Research
Our lab focuses on developing innovative therapies and understanding fundamental biological processes. We are developing nanotherapies for cardiovascular disease and uncovering new antiviral defense mechanisms within the placenta, both with the goal of improving human health.
Atherosclerotic Cardiovascular Disease
injured arteries treated with cell selective
Ad-p27-126Ts miRNA switch
exhibiting restenosis after balloon injury
Our lab aimed to develop cell-selective nanotherapy to combat atherosclerotic cardiovascular disease. This therapy specifically targets inflammatory and vascular smooth muscle cells, which are key players in plaque buildup, while carefully preserving healthy endothelial cells.
Initially, we employed an adenoviral vector, but our current focus is on a more advanced synthetic mRNA-based miRNA switch technology encapsulated in nanoparticles.
This innovative approach effectively delivers therapeutic payloads directly to damaged vessel areas, significantly reducing plaque formation and promoting vessel repair. We are actively enhancing this technology by combining it with siRNA to further suppress inflammation, in an effort to restore the endothelial barrier while inhibiting the progression of atherosclerotic plaque.
Transposable Elements and Antiviral Defense